These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 36480113)

  • 1. A narrative review of vaccine pharmacovigilance during mass vaccination campaigns: Focus on myocarditis and pericarditis after COVID-19 mRNA vaccination.
    Piché-Renaud PP; Morris SK; Top KA
    Br J Clin Pharmacol; 2023 Mar; 89(3):967-981. PubMed ID: 36480113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada.
    Buchan SA; Seo CY; Johnson C; Alley S; Kwong JC; Nasreen S; Calzavara A; Lu D; Harris TM; Yu K; Wilson SE
    JAMA Netw Open; 2022 Jun; 5(6):e2218505. PubMed ID: 35749115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review.
    Pillay J; Gaudet L; Wingert A; Bialy L; Mackie AS; Paterson DI; Hartling L
    BMJ; 2022 Jul; 378():e069445. PubMed ID: 35830976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study.
    Massari M; Spila Alegiani S; Morciano C; Spuri M; Marchione P; Felicetti P; Belleudi V; Poggi FR; Lazzeretti M; Ercolanoni M; Clagnan E; Bovo E; Trifirò G; Moretti U; Monaco G; Leoni O; Da Cas R; Petronzelli F; Tartaglia L; Mores N; Zanoni G; Rossi P; Samez S; Zappetti C; Marra AR; Menniti Ippolito F;
    PLoS Med; 2022 Jul; 19(7):e1004056. PubMed ID: 35900992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative assessment of myocarditis and pericarditis reporting rates related to mRNA COVID-19 vaccines in Europe and the United States.
    Hatziantoniou S; Anastassopoulou C; Lazaros G; Vasileiou K; Tsioufis C; Tsakris A
    Expert Rev Vaccines; 2022 Nov; 21(11):1691-1696. PubMed ID: 35815358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myocarditis and/or pericarditis risk after mRNA COVID-19 vaccination: A Canadian head to head comparison of BNT162b2 and mRNA-1273 vaccines.
    Abraham N; Spruin S; Rossi T; Fireman B; Zafack J; Blaser C; Shaw A; Hutchings K; Ogunnaike-Cooke S
    Vaccine; 2022 Jul; 40(32):4663-4671. PubMed ID: 35750537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Booster dose of COVID-19 mRNA vaccine does not increase risks of myocarditis and pericarditis compared with primary vaccination: New insights from the vaccine adverse event reporting system.
    Chen C; Fu F; Ding L; Fang J; Xiao J
    Front Immunol; 2022; 13():938322. PubMed ID: 36172346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccines.
    Le Vu S; Bertrand M; Jabagi MJ; Botton J; Drouin J; Baricault B; Weill A; Dray-Spira R; Zureik M
    Nat Commun; 2022 Jun; 13(1):3633. PubMed ID: 35752614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Risk of Myocarditis/Pericarditis Following Second Doses of BNT162b2 and mRNA-1273 Coronavirus Vaccines.
    Naveed Z; Li J; Wilton J; Spencer M; Naus M; Velásquez García HA; Kwong JC; Rose C; Otterstatter M; Janjua NZ;
    J Am Coll Cardiol; 2022 Nov; 80(20):1900-1908. PubMed ID: 36357091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence, Clinical Presentation, and Management of Myocarditis following mRNA-Based Covid-19 Vaccines: A Brief Report.
    Saeed S; Käsk L; Rajani R; Larsen TH
    Cardiology; 2022; 147(4):406-412. PubMed ID: 35104821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myocarditis or Pericarditis Events After BNT162b2 Vaccination in Individuals Aged 12 to 17 Years in Ontario, Canada.
    Buchan SA; Alley S; Seo CY; Johnson C; Kwong JC; Nasreen S; Thampi N; Lu D; Harris TM; Calzavara A; Wilson SE
    JAMA Pediatr; 2023 Apr; 177(4):410-418. PubMed ID: 36848096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac complications following mRNA COVID-19 vaccines: A systematic review of case reports and case series.
    Fazlollahi A; Zahmatyar M; Noori M; Nejadghaderi SA; Sullman MJM; Shekarriz-Foumani R; Kolahi AA; Singh K; Safiri S
    Rev Med Virol; 2022 Jul; 32(4):e2318. PubMed ID: 34921468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pericarditis and myocarditis after COVID-19 mRNA vaccination in a nationwide setting.
    Yap J; Tham MY; Poh J; Toh D; Chan CL; Lim TW; Lim SL; Chia YW; Lim YT; Choo J; Ding ZP; Foo LL; Kuo S; Lau YH; Lee A; Yeo KK
    Ann Acad Med Singap; 2022 Feb; 51(2):96-100. PubMed ID: 35224605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance.
    Nasreen S; Calzavara A; Buchan SA; Thampi N; Johnson C; Wilson SE; Kwong JC;
    Vaccine; 2022 May; 40(24):3305-3312. PubMed ID: 35527057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination.
    Goddard K; Lewis N; Fireman B; Weintraub E; Shimabukuro T; Zerbo O; Boyce TG; Oster ME; Hanson KE; Donahue JG; Ross P; Naleway A; Nelson JC; Lewin B; Glanz JM; Williams JTB; Kharbanda EO; Katherine Yih W; Klein NP
    Vaccine; 2022 Aug; 40(35):5153-5159. PubMed ID: 35902278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myocarditis and pericarditis in adolescents after first and second doses of mRNA COVID-19 vaccines.
    Foltran D; Delmas C; Flumian C; De Paoli P; Salvo F; Gautier S; Drici MD; Karsenty C; Montastruc F
    Eur Heart J Qual Care Clin Outcomes; 2022 Mar; 8(2):99-103. PubMed ID: 34849667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases.
    Wong HL; Hu M; Zhou CK; Lloyd PC; Amend KL; Beachler DC; Secora A; McMahill-Walraven CN; Lu Y; Wu Y; Ogilvie RP; Reich C; Djibo DA; Wan Z; Seeger JD; Akhtar S; Jiao Y; Chillarige Y; Do R; Hornberger J; Obidi J; Forshee R; Shoaibi A; Anderson SA
    Lancet; 2022 Jun; 399(10342):2191-2199. PubMed ID: 35691322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reports of myocarditis and pericarditis following mRNA COVID-19 vaccination: a systematic review of spontaneously reported data from the UK, Europe and the USA and of the scientific literature.
    Lane S; Yeomans A; Shakir S
    BMJ Open; 2022 May; 12(5):e059223. PubMed ID: 35613761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac Complications After SARS-CoV-2 Infection and mRNA COVID-19 Vaccination - PCORnet, United States, January 2021-January 2022.
    Block JP; Boehmer TK; Forrest CB; Carton TW; Lee GM; Ajani UA; Christakis DA; Cowell LG; Draper C; Ghildayal N; Harris AM; Kappelman MD; Ko JY; Mayer KH; Nagavedu K; Oster ME; Paranjape A; Puro J; Ritchey MD; Shay DK; Thacker D; Gundlapalli AV
    MMWR Morb Mortal Wkly Rep; 2022 Apr; 71(14):517-523. PubMed ID: 35389977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review of spontaneous reports of myocarditis and pericarditis in transplant recipients and immunocompromised patients following COVID-19 mRNA vaccination.
    Lane S; Yeomans A; Shakir S
    BMJ Open; 2022 Jul; 12(7):e060425. PubMed ID: 35777878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.